Imaging markers for Alzheimer disease: Which vs how

Neurology

Volumn 81, Issue 5, 2013, Pages 487-500

  Frisoni, Giovanni B ^a   Bocchetta, Martina ^a   Chételat, Gael ^b,c,d,e   Rabinovici, Gil D ^f   De Leon, Mony J ^h   Kaye, Jeffrey ^i,j   Reiman, Eric M ^k   Scheltens, Philip ^l   Barkhof, Frederik ^m   Black, Sandra E ⁿ   Brooks, David J ^o,p   Carrillo, Maria C ^ab   Fox, Nick C ^q   Herholz, Karl ^r   Nordberg, Agneta ^s,t   Jack, Clifford R ^u   Jagust, William J ^v   Johnson, Keith A ^w   Rowe, Christopher C ^x   Sperling, Reisa A ^w   Thies, William ^ab   Wahlund, Lars Olof ^t   Weiner, Michael W ^g,y   Pasqualetti, Patrizio ^z,aa   DeCarli, Charles ^g   more..

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b Centre Cyceron   (France)

^c UNIVERSITÉ DE CAEN   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Center for Brain Health   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j PORTLAND VA MEDICAL CENTER   (United States)

^k BANNER ALZHEIMER S INSTITUTE   (United States)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^m VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF TORONTO   (Canada)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

^p AARHUS UNIVERSITY   (Denmark)

^q UNIVERSITY COLLEGE LONDON   (United Kingdom)

^r UNIVERSITY OF MANCHESTER   (United Kingdom)

^s KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^t KAROLINSKA INSTITUTE   (Sweden)

^u MAYO CLINIC   (United States)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w BRIGHAM AND WOMEN S HOSPITAL   (United States)

^x AUSTIN HEALTH   (Australia)

^y SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^z FATEBENEFRATELLI HOSPITAL   (Italy)

^aa Medical Statistics Unit   (Italy)

^ab ALZHEIMER'S ASSOCIATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

ACCURACY; ALZHEIMER DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; METRIC SYSTEM; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84881287638     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31829d86e8     Document Type: Review

References (46)

1. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer̈s disease: revising the NINCDSADRDA criteria. Lancet Neurol 2007;6:734-746.
2. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer̈s disease: a new lexicon. Lancet Neurol 2010;9:1118-1127.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer̈s disease: recommendations from the National Institute on Aging-Alzheimer̈s Association Workgroups on Diagnostic Guidelines for Alzheimer̈s Disease. Alzheimers Dement 2011;7:280-292.
4. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer̈s disease: recommendations from the National Institute on Aging-Alzheimer̈s Association Workgroups on Diagnostic Guidelines for Alzheimer̈s Disease. Alzheimers Dement 2011;7:270-279.
5. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer̈s disease: recommendations from the National Institute on Aging-Alzheimer̈s Association Workgroups on Diagnostic Guidelines for Alzheimer̈s Disease. Alzheimers Dement 2011;7:263-269.
6. Khachaturian ZS. Revised criteria for diagnosis of Alzheimer̈s disease: National Institute on Aging-Alzheimer̈s Association Diagnostic Guidelines for Alzheimer̈s Disease. Alzheimers Dement 2011;7:253-256.
7. Frisoni GB, Hampel H, ÖBrien JT, Ritchie K,Winblad B. Revised criteria for Alzheimer̈s disease: what are the lessons for clinicians? Lancet Neurol 2011;10:598-601.
8. Frisoni GB, Winblad B, ÖBrien JT. Revised NIA-AA criteria for the diagnosis of Alzheimer̈s disease: a step forward but not yet ready for widespread clinical use. Int Psychogeriatr 2011;23:1191-1196.
9. Gauthier S, Patterson C, Gordon M, Soucy JP, Schubert F, Leuzy A. Commentary on "Recommendations from the National Institute on Aging-Alzheimer̈s Association Workgroups on Diagnostic Guidelines for Alzheimer̈s Disease." A Canadian perspective. Alzheimers Dement 2011;7:330-332.
10. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012;11: 669-678.
11. Yang L, Rieves D, Ganley C. Brain amyloid imaging: FDA approval of florbetapir F18 injection. N Engl J Med 2012; 367:885-887.
12. European Medicines Agency. Amyvid (florbetapir 18F). EMA/696925/2012, EMEA/H/C/0022422; January 2013.
13. Committee for Medicinal Products for Human Use (CHMP). Qualification opinion of low hippocampal volume (atrophy) by MRI for use in clinical trials for regulatory purpose: in pre-dementia stage of Alzheimer̈s disease. EMA/CHMP/SAWP/809208/2011; November 17, 2011.
14. Committee for Medicinal Products for Human Use (CHMP). Qualification opinion of Alzheimer̈s disease novel methodologies/biomarkers for PET amyloid imaging (positive/negative) as a biomarker for enrichment, for use in regulatory clinical trials in predementia Alzheimer̈s disease. EMA/CHMP/SAWP/892998/2011; February 16, 2012.
15. Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer̈s disease. J Alzheimers Dis 2011;26:627-645.
16. Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med 2012;53:59-71.
17. Chetelat G, Baron JC. Early diagnosis of Alzheimer̈s disease: contribution of structural neuroimaging. Neuroimage 2003;18:525-541.
18. Devous MD Sr. Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies. Eur J Nucl Med Mol Imaging 2002;29:1685-1696.
19. Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 2004;12:554-570.
20. Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer̈s disease. Lancet Neurol 2011;10:667-670.
21. Jack CR Jr. Alliance for Aging Research AD Biomarkers Work Group: structural MRI. Neurobiol Aging 2011;32 (suppl 1):S48-S57.
22. Laforce R Jr, Rabinovici GD. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther 2011;3:31.
23. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer̈s disease: FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510.
24. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT. Alzheimer disease: operating characteristics of PET-A meta-analysis. Radiology 2004;231:73-80.
25. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positronemission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 2009;30: 404-410.
26. Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of (18) F-FDG and (11) C-PIB-PET for prediction of short-term conversion to Alzheimer̈s disease in subjects with mild cognitive impairment. Int J Clin Pract 2012;66:185-198.
27. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-316.
28. Chen K, Ayutyanont N, Langbaum JB, et al. Characterizing Alzheimer̈s disease using a hypometabolic convergence index. Neuroimage 2011;56:52-60.
29. Fischl B, Dale A. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 2000;97:11050-11055.
30. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341-355.
31. Morra JH, Tu Z, Apostolova LG, et al. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer̈s disease, mild cognitive impairment, and elderly controls. Neuroimage 2008;43:59-68.
32. Chupin M, Mukuna-Bantumbakulu AR, Hasboun D, et al. Anatomically constrained region deformation for the automated segmentation of the hippocampus and the amygdala: method and validation on controls and patients with Alzheimer̈s disease. Neuroimage 2007;34:996-1019.
33. Jaeschke R, Guyatt GH, Sackett DL. Users̈ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994;271:703-707.
34. Albert J. Bayesian Computation with R. New York: Springer; 2009.
35. Jack CR Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criteria for Alzheimer̈s disease. Alzheimers Dement 2011;7:474-485.e4.
36. Thurfjell L, Lotjonen J, Lundqvist R, et al. Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener Dis 2012;10:246-249.
37. Morinaga A, Ono K, Ikeda T, et al. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer̈s disease in a memory clinic. Dement Geriatr Cogn Disord 2010; 30:285-292.
38. Visser PJ, Scheltens P, Verhey FR, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol 1999;246:477-485.
39. Fritzsche KH, Stieltjes B, Schlindwein S, van Bruggen T, Essig M, Meinzer HP. Automated MR morphometry to predict Alzheimer̈s disease in mild cognitive impairment. Int J Comput Assist Radiol Surg 2010; 5:623-632.
40. Cuingnet R, Gerardin E, Tessieras J, et al. Automatic classification of patients with Alzheimer̈s disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage 2011;56:766-781.
41. Ewers M, Walsh C, Trojanowski JQ, et al. Prediction of conversion from mild cognitive impairment to Alzheimer̈s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012;33:1203-1214.
42. Bhadra D, Daniels MJ, Kim S, Ghosh M, Mukherjee B. A bayesian semiparametric approach for incorporating longitudinal information on exposure history for inference in case-control studies. Biometrics 2012;68:361-370.
43. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer̈s disease. Science 2006;314: 781-784.
44. Frisoni GB, Redolfi A, Manset D, Rousseau ME, Toga A, Evans AC. Virtual imaging laboratories for marker discovery in neurodegenerative diseases. Nat Rev Neurol 2011;7: 429-438.
45. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005;64:1860-1867.
46. Mattsson N, Rosen E, Hansson O, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012;78:468-476.